News | July 21, 2025
Aarti Drugs posts Q1 FY26 PAT higher at Rs. 54 Cr
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
The INSPIRE-1 and INSPIRE-2 trials are Phase 3 studies assessing the efficacy and safety of tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis (PsA)
Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials
Neuberg group commits to invest over Rs. 100 crores to start diagnostics facilities across Jharkhand in the next 2-3 years
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
The new Zigly center features and offers comprehensive veterinary services
Phosphate-based excipients provide higher bulk densities and enable the reduction of the tablet sizes
This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms
There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
Subscribe To Our Newsletter & Stay Updated
